Anaptys Announces Top-Line Phase 3 Clinical Trial Results Of Imsidolimab In Generalized Pustular Psoriasis
Portfolio Pulse from Benzinga Newsdesk
AnaptysBio, Inc. (NASDAQ:ANAB) announced positive top-line results from its global Phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab in patients with generalized pustular psoriasis (GPP). The trial met its primary endpoint with 53.3% of patients achieving clear or almost clear skin at Week 4 after a single dose of 750mg IV imsidolimab, compared to 13.3% of patients on placebo. The company plans to present comprehensive data from GEMINI-1 and top-line GEMINI-2 results at a medical meeting in H2 2024 and intends to out-license imsidolimab in 2024.
October 09, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AnaptysBio's positive trial results for imsidolimab could potentially boost its stock in the short term. The company's plan to out-license the drug in 2024 could also attract investors.
Positive clinical trial results often lead to increased investor confidence and a rise in the company's stock price. The company's plan to out-license imsidolimab in 2024 could also be seen as a positive move, potentially leading to increased revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100